Search results
Results from the WOW.Com Content Network
Inspire Medical’s outlook for 2025 is based on plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and boost capacity.
MINNEAPOLIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Jefferies London ...
Inspire (INSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of ...
In April 2018, an Inspire data scientist was an author of a Nature Genetics correspondence [16] about ways to close the"terminology gap" between medical professionals and patients. Also in 2018, Inspire collaborated with ProPublica and Memorial Sloan Kettering Cancer Center in research that led to a paper in the Journal of Oncology Practice .
McGuire has co-founded three companies: Inspire Pharmaceuticals, AIR (Advanced Inhalation Research, Inc.), and MicroCHIPS. AIR has created a drug delivery method that allows drugs to be inhaled into the lungs. Companies Terry has supported have touched more than 60 million patients and directly saved over 400,000 lives.
Colorectal Cancer Alliance is the largest and oldest colorectal cancer non-profit organization in the US.. The Colorectal Cancer Alliance offers a variety of patient support services including grant programs, monthly webinars, a helpline, chat forum and a Buddy Program, which provides both survivors and caregivers with a chance to connect with someone who has gone through a similar experience.
Inspire (INSP) delivered earnings and revenue surprises of 7.69% and 9.18%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?